top of page
Browse by category
Search
CMS' semaglutide coverage expansion could save millions of lives
A group of 44 health care and advocacy organizations is urging the Centers for Medicare & Medicaid Services (CMS) to expand coverage and...
FDA approves Wegovy for CVD risk reduction in people with overweight or obesity and established cardiovascular disease
The FDA has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing...
FLOW trial: Semaglutide 1.0mg demonstrates 24% reduction in the risk of kidney disease-related events in T2DM and chronic kidney disease patients
Headline results from the kidney outcomes trial FLOW (Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in...
Novo Nordisk to end semaglutide kidney study early due to strong efficacy signals
Novo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide...
Study links GLP-1s with serious gastrointestinal conditions
Glucagon-like peptide-1 (GLP-1) agonists are associated with an increased risk of serious medical conditions including stomach paralysis,...
Rejuva GLP-1-based pancreatic gene therapy candidate results in greater weight loss vs. semaglutide
Fractyl Health has revealed preclinical findings from its Rejuva gene therapy platform at the European Association for the Study of...
Journal Watch 4/10/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Browse by tag
bottom of page